Idronoxil

Drug Overview

Idronoxil, also known by its chemical name phenoxodiol and its clinical formulation name NOX66, is an investigational Targeted Therapy and radiosensitizer developed by Australian company Noxopharm Limited. It is a synthetic flavonoid derivative of genistein that inhibits external NADH oxidase 2 (ENOX2) to induce apoptosis and cell cycle arrest, and inhibit DNA topoisomerase 2.

What makes idronoxil uniquely positioned in oncology is its dual role: it acts both as a direct cancer cell killer and as a chemosensitizer restoring sensitivity to chemotherapy and radiation in tumors that have developed drug resistance. Its NOX66 suppository formulation was specifically developed to overcome poor bioavailability that hampered earlier oral and IV formulations.

• Generic Name: Idronoxil (phenoxodiol)
• US Brand Name: Veyonda (investigational; NOX66 as suppository formulation)
• Drug Class: ENOX2 Inhibitor / Synthetic Isoflavone Analog / Radiosensitizer / Targeted Therapy
• Route of Administration: Rectal suppository (NOX66); earlier formulations studied as IV infusion and oral tablet
• FDA Approval Status: Not FDA-approved. Idronoxil is under active clinical investigation in multiple phase I/II trials across prostate cancer, head and neck cancer, and other solid tumors. Idronoxil has been the subject of more than 50 peer-reviewed publications over the last two decades.

What Is It and How Does It Work? (Mechanism of Action)

The primary mechanism of action of idronoxil stems from its binding to the transmembrane enzyme ENOX2 expressed on cancer cells, resulting in reduced S1P and increased ceramide levels, thereby promoting apoptosis. Here is how this process works step by step:

ENOX2 Inhibition — Cancer-Selective Targeting: The targeted effect on ENOX2 has the potential to limit toxicity to noncancer cells, which preferentially express ENOX1. By selectively binding ENOX2 — an enzyme found predominantly on cancer cell surfaces — idronoxil delivers its anti-cancer effects with minimal disruption to healthy tissues.

Ceramide Pathway Activation and Akt Shutdown: ENOX2 inhibition activates the sphingomyelinase pathway and deactivates the antiapoptotic protein kinase B (Akt) pathway, a key driver of radiotherapy resistance. When Akt is deactivated, cancer cells lose one of their most critical survival signals, making them vulnerable to both the immune system and co-administered cancer treatments.

Restoring Apoptosis: Idronoxil targets dysregulated prosurvival pathways mediated via Akt, FLIP, and XIAP in cancer cells, restoring caspase-mediated apoptosis. In drug-resistant tumors, these prosurvival proteins act like shields. Idronoxil removes these shields, allowing the cell’s own self-destruction machinery to function again.

Radiosensitization: Additional intracellular effects include the inhibition of DNA repair mechanisms. By blocking cancer cells from repairing radiation-induced DNA damage, idronoxil dramatically enhances the effectiveness of radiotherapy — allowing lower radiation doses to achieve superior tumor control.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Metastatic Castration-Resistant Prostate Cancer (mCRPC) — primary investigational focus; studied in combination with external beam radiotherapy (EBRT) and with 177Lu-PSMA-617 radioligand therapy
• Head and Neck Cancer — under investigation in combination with radiotherapy
• Other Solid Tumors — including breast cancer and non-small cell lung cancer (NSCLC), studied in phase 1b/2a expansion cohorts

Non-Oncological Uses:

• Preclinical data has explored idronoxil’s TBK1-inhibiting anti-inflammatory activity in COVID-19, though no formal clinical indications have been pursued in this area.

Dosage and Administration Protocols

Early studies of intravenous and oral formulations of idronoxil were hampered by limited bioavailability. NOX66 is a suppository formulation of idronoxil, minimising phase 2 metabolism in the liver via rectal administration. In all current trials, NOX66 is administered daily for 10 consecutive days per treatment cycle, concurrent with radiotherapy or radioligand therapy.

Clinical Efficacy and Research Results

Idronoxil’s most compelling clinical evidence comes from the LuPIN trial — a phase I/II study combining NOX66 with 177Lu-PSMA-617 radioligand therapy in heavily pretreated end-stage mCRPC patients.

In the expanded LuPIN cohort of 56 patients, 48 of 56 had a reduction in PSA level (86%; 95% CI, 74%–94%); 34 of 56 (61%; 95% CI, 47%–74%) had a PSA reduction of at least 50%. Median PSA progression-free survival was 7.5 months (95% CI, 5.9–9 months), and median overall survival was 19.7 months (95% CI, 9.5–30 months).

In the earlier radiation combination DARRT trial (NCT03307629), 25 patients received and completed treatment. At 6 months, of the 15 evaluable patients by RECIST 1.1, 9 had stable disease and 1 had a partial response. Five of the 16 PSA-evaluable patients achieved a PSA response (61–98% PSA reduction) at 6 months.

These results are particularly remarkable given that all enrolled patients had already failed multiple lines of standard treatment — including docetaxel, cabazitaxel, abiraterone, and enzalutamide — representing one of the most treatment-refractory populations in oncology.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for idronoxil, as it is not FDA-approved. The clinical program has demonstrated a consistently mild and manageable safety profile across all formulations and dose levels studied.

Common Side Effects (>10%):

• Anal Irritation — the most formulation-specific side effect of the rectal suppository; anal irritation attributable to NOX66 occurred in 38% of patients in the LuPIN trial; generally grade 1 and manageable with topical emollients
• Fatigue — mild (Grade 1); attributed to combined effects of NOX66 and radiation/radioligand therapy
• Anemia — with only anemia considered to be possibly related to NOX66 in the safety analysis; monitor hemoglobin throughout treatment
• Xerostomia (Dry Mouth) — mild, Grade 1; reported in patients receiving concurrent radioligand therapy

Serious Adverse Events:

• None of the 21 Grade ≥3 treatment-emergent adverse events were considered related to NOX66 — a particularly favorable finding for a drug used in heavily pretreated, end-stage patients
• Thrombocytopenia: Transient low platelet counts were reported with earlier IV formulations, attributed to the cyclodextrin excipient rather than idronoxil itself; not observed with the NOX66 suppository formulation
• Embryo-Fetal Toxicity: Theoretical risk based on apoptosis-activating mechanism; contraception required for patients of reproductive potential

Management Strategies:

• For anal irritation: apply topical emollients before and after suppository insertion; consider dose adjustment if Grade 2 or higher
• For anemia: monitor hemoglobin before each cycle; transfusion support as clinically indicated
• For fatigue: rule out underlying disease progression or anemia before attributing to drug

Connection to Stem Cell and Regenerative Medicine

Idronoxil’s ENOX2-selective mechanism gives it a meaningful connection to bone marrow and stem cell preservation. The targeted effect on ENOX2 has the potential to limit toxicity to noncancer cells, which preferentially express ENOX1 — including hematopoietic stem cells in the bone marrow. This selectivity means idronoxil is unlikely to cause the stem cell toxicity that limits many conventional chemotherapy agents. Its radiosensitizing properties are now being explored in combination with radioligand therapies that themselves require intact bone marrow reserve, making idronoxil’s bone marrow-sparing profile a clinically critical advantage in the context of multi-cycle radioligand treatment.

Disclaimer: These studies regarding idronoxil, ENOX2 selectivity, and marrow-sparing potential are still evolving and are not yet applicable to practical or professional clinical scenarios. While ENOX2 targeting may offer a theoretical advantage over nonselective chemotherapy, the discussion regarding guaranteed stem-cell preservation, negligible marrow toxicity, or established clinical superiority in radioligand combinations remain exploratory and should be interpreted cautiously.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• PSA level and complete blood count (CBC) — baseline and before each cycle
• 68Ga-PSMA PET/CT and 18F-FDG PET/CT — required for patient selection in LuPIN-type trials
• Liver function tests (LFTs) and kidney function panel
• Testosterone level to confirm castration-resistant status in prostate cancer patients

Precautions During Treatment:

• Patients must meet PSMA imaging eligibility criteria before enrolling in radioligand combination trials
• Monitor CBC and PSA before each 6-week treatment cycle
• Idronoxil is only available through participation in an approved clinical trial

Do’s and Don’ts:

• DO administer the NOX66 suppository at the same time each day during the 10-day dosing window
• DO report any significant rectal discomfort, bleeding, or pain to your care team immediately
• DO attend all scheduled PSA tests, imaging appointments, and safety monitoring visits
• DON’T use idronoxil outside of an approved and supervised clinical trial program
• DON’T miss any scheduled radioligand therapy infusion days — timing with NOX66 is clinically critical
• DON’T become pregnant during treatment — the apoptotic mechanism carries theoretical fetal risk

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Idronoxil (NOX66/Veyonda) is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.